Genenta Science (NASDAQ:GNTA) Shares Down 3.1% – Time to Sell?

Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) was down 3.1% during mid-day trading on Monday . The stock traded as low as $1.2350 and last traded at $1.26. 59,577 shares were traded during mid-day trading, an increase of 3% from the average daily volume of 58,073 shares. The stock had previously closed at $1.30.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered Genenta Science from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

Genenta Science Stock Performance

The company has a quick ratio of 14.16, a current ratio of 14.16 and a debt-to-equity ratio of 0.35. The stock’s fifty day simple moving average is $1.57 and its 200-day simple moving average is $1.11.

Institutional Trading of Genenta Science

A number of hedge funds have recently bought and sold shares of GNTA. Eurizon Capital SGR S.p.A. acquired a new position in Genenta Science in the 4th quarter valued at $536,000. Weiss Asset Management LP purchased a new stake in shares of Genenta Science in the fourth quarter valued at $480,000. Ghisallo Capital Management LLC acquired a new position in Genenta Science in the fourth quarter valued at $482,000. Alyeska Investment Group L.P. purchased a new position in Genenta Science during the fourth quarter worth about $328,000. Finally, SmartHarvest Portfolios LLC purchased a new position in Genenta Science during the fourth quarter worth about $26,000. Institutional investors and hedge funds own 15.13% of the company’s stock.

Genenta Science Company Profile

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.